After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing in the Rain.” ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. See why RXRX stock is a Hold.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding ...

Best known for the Recursion Studio, Entropy & Sons crafts devices that allow users to generate high-definition, real-time visual compositions without a computer.

Recursion Pharmaceuticals faces a 57% stock drop amid drug setbacks, rising cash burn, and AI discovery doubts. Learn more about RXRX stock here.

AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...